CCA exhibits relatively few druggable targets, though novel molecular targets such as fibroblast growth factor receptor-2 (FGFR2) and isocitrate dehydrogenase-1 (IDH1) mutations have been identified as promising within phase 2/3 trials in CCA patients harboring such alterations [12–14]. Here, FGFR2 is linked to cholangiocarcinoma.